Lipid droplets can promote drug accumulation and activation

Area of Science:

• Cell Biology
• Pharmacology
• Genetics

Background:

• Genetic screens in human cells identify pathways influencing drug efficacy.
• Lasonolide A (LasA) is a potent macrolide anticancer agent derived from marine sponges.
• Understanding drug sensitivity mechanisms is crucial for clinical development.

Purpose of the Study:

• To identify genes essential for sensitivity to the anticancer drug lasonolide A (LasA).
• To elucidate the mechanism by which LasA exerts its cytotoxic effects.
• To explore the role of lipid droplets in drug metabolism and toxicity.

Main Methods:

• Utilized insertional mutagenesis-based genetic screens in haploid human cells.
• Performed mechanistic studies to investigate gene function and drug-target interactions.
• Employed cell biology techniques to analyze drug localization and metabolism.

Main Results:

• Convergent genetic screens identified LDAH as the sole gene required for LasA sensitivity.
• LDAH encodes a serine hydrolase located on lipid droplet surfaces.
• LasA accumulates in lipid droplets and is activated by LDAH into a toxic metabolite.

Conclusions:

• LDAH is a critical enzyme for lasonolide A activation and cancer cell killing.
• Lipid droplets serve as a platform for drug accumulation and activation.
• Drug partitioning into lipid droplets influences activation and cellular toxicity, suggesting novel therapeutic strategies.